[go: up one dir, main page]

WO2006039399A3 - Decroissance de l'arnm mediee par staufen 1 (stau1) - Google Patents

Decroissance de l'arnm mediee par staufen 1 (stau1) Download PDF

Info

Publication number
WO2006039399A3
WO2006039399A3 PCT/US2005/035011 US2005035011W WO2006039399A3 WO 2006039399 A3 WO2006039399 A3 WO 2006039399A3 US 2005035011 W US2005035011 W US 2005035011W WO 2006039399 A3 WO2006039399 A3 WO 2006039399A3
Authority
WO
WIPO (PCT)
Prior art keywords
mrna decay
staufen
mediated mrna
stau1
staul
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/035011
Other languages
English (en)
Other versions
WO2006039399A2 (fr
Inventor
Lynne E Maquat
Yoon Ki Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester filed Critical University of Rochester
Publication of WO2006039399A2 publication Critical patent/WO2006039399A2/fr
Anticipated expiration legal-status Critical
Publication of WO2006039399A3 publication Critical patent/WO2006039399A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des compositions et des méthodes de traitement de patients présentant des états résultant d'une décroissance de l'ARNm médiée par Stau1, de criblage et de production de ces agents thérapeutiques. L'invention concerne de nouveaux mécanismes de décroissance de l'ARNm faisant intervenir Staufen mammifère (Stau)1, le facteur Upf1 de décroissance d'ARNm à médiation nonsens (NMD), ainsi qu'un codon de terminaison. Il est montré que Stau1 se fixe directement au Upf1 et peut mettre en lumière une décroissance de l'ARNm lorsqu'il est attaché en aval d'un codon de terminaison. L'invention concerne également la nouvelle voie constituant un moyen permettant aux cellules de réguler négativement l'expression des ARNm liant Stau1.
PCT/US2005/035011 2004-09-29 2005-09-29 Decroissance de l'arnm mediee par staufen 1 (stau1) Ceased WO2006039399A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61407104P 2004-09-29 2004-09-29
US60/614,071 2004-09-29
US64684405P 2005-01-25 2005-01-25
US60/646,844 2005-01-25

Publications (2)

Publication Number Publication Date
WO2006039399A2 WO2006039399A2 (fr) 2006-04-13
WO2006039399A3 true WO2006039399A3 (fr) 2007-04-19

Family

ID=36143051

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/035011 Ceased WO2006039399A2 (fr) 2004-09-29 2005-09-29 Decroissance de l'arnm mediee par staufen 1 (stau1)

Country Status (1)

Country Link
WO (1) WO2006039399A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102089444A (zh) 2008-05-14 2011-06-08 德玛泰克国际公司 利用核酸分析方法来诊断黑素瘤和太阳能雀斑
US9206479B2 (en) 2011-02-09 2015-12-08 University Of Rochester Methods and compositions related to Staufen 1 binding sites formed by duplexing Alu elements
WO2016179043A1 (fr) 2015-05-01 2016-11-10 Dermtech, Inc. Système non invasif de prélèvement de peau
EP3551641A4 (fr) * 2016-12-08 2021-01-13 University of Utah Research Foundation Agents de la staufen1 et procédés associés
EP3752645A4 (fr) 2018-02-14 2022-04-13 Dermtech, Inc. Nouveaux classificateurs de gènes et leurs utilisations dans des cancers de la peau sans mélanome
US11946046B2 (en) 2018-06-14 2024-04-02 University Of Utah Research Foundation Staufen1 regulating agents and associated methods
WO2020198229A1 (fr) 2019-03-26 2020-10-01 Dermtech, Inc. Nouveaux classificateurs de gènes et leurs utilisations pour des cancers de la peau

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US20040241845A1 (en) * 1998-05-22 2004-12-02 Luc Desgroseillers Mammalian staufen and use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US20040241845A1 (en) * 1998-05-22 2004-12-02 Luc Desgroseillers Mammalian staufen and use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FERRAIUOLO ET AL: "A role for the elF4E-binding protein 4E-T in P-body formation and mRNA decay", THE JOURNAL OF CELL BIOLOGY, vol. 170, 12 September 2005 (2005-09-12), pages 913 - 924, XP003010912 *
KIM ET AL: "Mammalian Staufen1 recruits Upfl to specific mRNA 3'UTR so as to elicit mRNA decay", CELL, vol. 120, 28 January 2005 (2005-01-28), pages 195 - 208, XP003010913 *
MEYER E.L. ET AL: "Staufen does double duty", NATURE STRUCTURAL & MOLECULAR BIOLOGY, vol. 12, 4 April 2005 (2005-04-04), pages 291 - 292, XP003010911 *

Also Published As

Publication number Publication date
WO2006039399A2 (fr) 2006-04-13

Similar Documents

Publication Publication Date Title
Sasse et al. Asymmetric localizations of the ABC transporter PaPDR1 trace paths of directional strigolactone transport
Li et al. Bibliometric analysis on global Parkinson's disease research trends during 1991–2006
WO2012109476A3 (fr) Procédés et compositions associés à des sites de liaison à staufen 1 formés par des éléments alu en duplex
WO2006039399A3 (fr) Decroissance de l'arnm mediee par staufen 1 (stau1)
WO2007016431A3 (fr) Nouveaux derives de benzo[d][1,3]-dioxol
WO2007103282A3 (fr) Cellules precurseurs endocrines, cellules exprimant des hormones pancreatiques et procedes de productions associes
NZ602248A (en) Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions
SG149061A1 (en) Definitive endoderm
WO2003078588A3 (fr) Cellules souches hepatiques primitives et proximales
Kumar et al. Hairy root induction in Helicteres isora L. and production of diosgenin in hairy roots
PL1845907T3 (pl) Orteza i sposób jej wytwarzania
CN109481685A (zh) Cd317抑制剂在制备治疗肝癌的药物中的应用
WO2009009114A3 (fr) Compositions et procédés de traitement et de diagnostic de cancer
WO2004026238A3 (fr) Compositions immunotherapeutiques et methodes permettant de traiter des cancers moderement a bien differencies
WO2009062260A8 (fr) Thérapie pour la sclérose en plaques
CN101942467A (zh) 双关键酶基因转化提高丹参毛状根丹参酮含量的方法
Mufson et al. Nerve growth factor receptor expressing human basal forebrain neurons: pathologic alterations in Alzheimer's and Parkinson's disease
WO2008021502A3 (fr) Procédés et compositions pour le retrait de cellules à partir de matériau de collecte
Hou et al. Metabolic engineering of Saccharomyces cerevisiae for de novo dihydroniloticin production using novel CYP450 from neem (Azadirachta indica)
WO2007035966A3 (fr) Aloes transgeniques utiles dans la production de proteines et procedes correspondants
WO2005005608A3 (fr) Compositions et procedes de differenciation de cellules adipeuses stromales en cellules beta pancreatiques
CN101362791A (zh) 一种甾体生物碱藜芦胺及其制备方法和降压应用
WO2006119346A3 (fr) Ketocarotenoides issus de adonis palaestina
WO2008054693A3 (fr) Utilisations de la tétrahydrobioptérine et de ses dérivés
Printz Agencies join forces to boost the number of veterans in cancer clinical trials: A new program is helping to make National Cancer Institute-sponsored trials more accessible to a vulnerable population

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase